Etaracizumab
|
WikiDoc Resources for Etaracizumab |
|
Articles |
|---|
|
Most recent articles on Etaracizumab Most cited articles on Etaracizumab |
|
Media |
|
Powerpoint slides on Etaracizumab |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Etaracizumab at Clinical Trials.gov Clinical Trials on Etaracizumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Etaracizumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Etaracizumab Discussion groups on Etaracizumab Patient Handouts on Etaracizumab Directions to Hospitals Treating Etaracizumab Risk calculators and risk factors for Etaracizumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Etaracizumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Etaracizumab (also known as etaratuzumab) is a humanized monoclonal antibody which it is used to treat metastatic melanoma and prostate cancer.